# US 2026/0083724 A1 · Compounds targeting pax3::foxo1 fusion protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083724 A1
- Document ID: US20260083724A1
- Status: Published application
- Kind: A1
- Application number: 19/341,825
- Filed: 2025-09-26
- Published: 2026-03-26
- Earliest claimed: 2024-09-26
- Assignees: Georgetown University
- Applicants: Georgetown University
- Inventors: Aykut Üren; Jeffrey A. Toretsky
- Web page: https://patentgrep.com/patent/US20260083724A1

## CPC

- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds comprising a PAX3::FOXO1 fusion protein binding moiety, a bivalent linker, and an E3 ubiquitin ligase binding moiety. The compounds can be used to reduce PAX3::FOXO1 protein levels in a subject with fusion-positive rhabdomyosarcoma (FP-RMS), to ubiquitinate a PAX3::FOXO1 fusion protein in a cell, to treat FP-RMS in a subject in need thereof, and/or to treat a disease caused by the overexpression of PAX3::FOXO1 protein in a subject in need thereof.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
P is a PAX3::FOXO1 fusion protein binding moiety;
L is a bivalent linker; and
U is an E3 ubiquitin ligase binding moiety; and
wherein the PAX3::FOXO1 fusion protein binding moiety comprises an agent selected from Table 1 or a derivative thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the PAX3::FOXO1 fusion protein binding moiety comprises an agent selected from NSC697468, alcuronium chloride, NSC2805, didanosine, carboplatin, piperacetazine, and derivatives thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the PAX3::FOXO1 fusion protein binding moiety comprises a derivative of piperacetazine selected from C6.12, C6.16, C6.21, C6.14, C6.15, C6.18a, and C.6.18b, or a pharmaceutically acceptable salt thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein the ubiquitin ligase binding moiety comprises a ligand that binds to an E3 ubiquitin ligase selected from Von Hippel-Lindau tumor suppressor protein (VHL), cereblon (CRBN), cellular inhibitor of apoptosis protein (cIAP), murine double minute 2 (MDM2), and S-phase kinase-associated protein 1 (SKP-1).

### Claim 6 (depends on 5)

The compound of claim 5, wherein the E3 ubiquitin ligase binding moiety comprises a ligand that binds to VHL, wherein the ligand is selected from VH032, VH101, VH298, and derivatives thereof.

### Claim 7

(canceled)

### Claim 8 (depends on 5)

The compound of claim 5, wherein the E3 ubiquitin ligase binding moiety comprises a ligand that binds to CRBN, wherein the ligand is selected from thalidomide, pomalidomide, lenalidomide, and derivatives thereof.

### Claim at position 9

9-13. (canceled)

### Claim 14 (depends on 5)

The compound of claim 5, wherein the E3 ubiquitin ligase binding moiety comprises a ligand that binds to SKP-1, wherein the ligand is EN884, or a derivative thereof selected from AD-5-49, AD-5-47a, and AD-5-47b.

### Claim at position 11

15-16. (canceled)

### Claim 17 (depends on 1)

The compound of claim 1, wherein the bivalent linker comprises one or more alkyl chains, polyethylene glycol (PEG) chains, extended glycol chains, or a combination thereof.

### Claim at position 13

18-19. (canceled)

### Claim 20 (depends on 8)

The compound of claim 8, wherein the E3 ubiquitin ligase binding moiety comprises pomalidomide.

### Claim 21 (depends on 20)

The compound of claim 20, wherein the PAX3::FOXO1 fusion protein binding moiety comprises NSC697468, and the compound is selected from the following:

### Claim 22

(canceled)

### Claim 23 (depends on 20)

The compound of claim 20, wherein the PAX3::FOXO1 fusion protein binding moiety is selected from C6.12, C6.16, C6.21, C6.14, C6.15, and a pharmaceutically acceptable salt thereof, and the compound is selected from the following:

### Claim 24

(canceled)

### Claim 25 (depends on 20)

The compound of claim 20, wherein the PAX3::FOXO1 fusion protein binding moiety comprises C6.18b or a pharmaceutically acceptable salt thereof, and the compound is selected from the following:

### Claim 26 (depends on 14)

The compound of claim 14, wherein the E3 ubiquitin ligase binding moiety comprises AD-5-47a.

### Claim 27 (depends on 26)

The compound of claim 26, wherein the PAX3::FOXO1 fusion protein binding moiety is selected from C6.12, C6.15, C6.18b, and a pharmaceutically acceptable salt thereof, and the compound is selected from the following:

### Claim 28 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 28)

A method of reducing PAX3::FOXO1 protein levels in a subject with fusion-positive rhabdomyosarcoma, the method comprising administering the pharmaceutical composition of claim 28 to the subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein the subject has fusion-positive alveolar rhabdomyosarcoma.

### Claim 31 (depends on 28)

A method of ubiquitinating a PAX3::FOXO1 fusion protein in a cell, the method comprising administering the pharmaceutical composition of claim 28 to the cell.

### Claim at position 26

32-33. (canceled)

### Claim 34 (depends on 28)

A method of treating fusion-positive rhabdomyosarcoma in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 28 to the subject.

### Claim 35

(canceled)

### Claim 36 (depends on 28)

A method of treating a disease caused by the overexpression of PAX3::FOXO1 protein in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 28 to the subject.

### Claim 37

(canceled)
